Seidenberg Beth C's Form 4 filing
Sagimet Biosciences Inc. (SGMT) · filed Jul 20, 2023
- Accession no.
- 0001104659-23-082736
- Filed
- Jul 20, 2023
- Trade date
- Jul 18, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 10 derivative transactions. Open-market purchases total $750.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Seidenberg Beth CCIK 0001184592 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2023 | Common Stock | DReturned to the companyDisposed | −38,763 | –F1 | – | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | AGrant or awardAcquired | +38,763 | –F1 | – | 38,763 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionAcquired | +1,860,712 | –F3 | – | 1,899,475 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionAcquired | +84,768 | –F3 | – | 84,768 | Direct | |
| Jul 18, 2023 | Series A Common Stock | PPurchaseAcquired | +46,875 | $16.00 | +$750,000 | 46,875 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −6,781 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −6,208 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −108,163 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −108,163 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −76,796 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −84,768 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −1,297,549 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Series A Common Stock | CConversionDisposed | −257,052 | $0.00 | $0 | 0 | Indirect | |
| Jul 18, 2023 | Common Stock | DReturned to the companyDisposed | −23,216 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Series A Common Stock | AGrant or awardAcquired | +23,216 | $0.00 | $0 | 23,216 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
Referenced by the price of 2 transactions in Table I.
- F3
Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I.